Wild-type p53 is stabilized and accumulates in the nucleus of DNA damaged cells. The eect of stabilizing p53 is to inhibit cell growth, either through a G1 cell cycle arrest or apoptotic cell death. MDM2 can inhibit p53 activity, in part, by promoting its rapid degradation through the ubiquitin proteolysis pathway. In the current study, MDM2-mediated degradation of p53 was partially inhibited in cells treated with leptomycin B (LMB), a speci®c inhibitor of nuclear export. In contrast, levels of ubiquitinated p53 increased in LMB-treated cells, indicating that nuclear export is not required for p53 ubiquitination. To investigate this further, p53 mutants were generated which localize to either the nucleus or cytoplasm, and their susceptibility to MDM2-mediated ubiquitination was assessed. p53 mutants that localized to either the nucleus or the cytoplasm were eciently ubiquitinated, and their steady-state levels decreased, when coexpressed with MDM2. In addition, an MDM2-mutant that localized to the cytoplasm was able to ubiquitinate and degrade a p53 mutant which was similarly localized in the cytoplasm. Our results indicate that nuclear export is not required for p53 ubiquitination, and that p53 proteins that localize to either the nucleus or cytoplasm can be ubiquitinated and degraded by MDM2. Oncogene (2000) 19, 5892 ± 5897.
Introduction
Wild-type p53 is a tumor suppressor protein and key regulator of cell growth. The activity most associated with the growth inhibitory function of p53 is its ability to bind DNA in a sequence speci®c manner and activate gene transcription (Funk et al., 1992; Kern et al., 1992; Pietenpol et al., 1994) . P53 levels are low in most cells, due to a short protein half-life. In contrast, p53 is stabilized and its levels increase in response to DNA damaging stress (Maltzman and Czyzyk, 1984; Maki and Howley, 1997) . The eect of increasing p53 is to stop cell proliferation, either through a G1 cell cycle arrest or apoptotic cell death (Lane, 1992; Levine, 1997) . These activities are mediated by p53-responsive genes, such as p21 and bax (Lane, 1992; Levine, 1997) . MDM2 forms an autoregulatory feedback loop in which p53 activates MDM2 transcription, and increased levels of MDM2 protein then bind p53 and inhibit its activity as a transcription factor (Momand et al., 1992; Oliner et al., 1992) . Importantly, MDM2 also promotes the rapid degradation of p53 through the ubiquitin proteolysis pathway (Haupt et al., 1997; Kubbutat et al., 1997; Fuchs et al., 1998) . This degradation may provide an eective means to rid cells of excess p53 during recovery from a DNA damage-induced cell cycle arrest.
In non-stressed cells p53 can exist in a latent, inactive form (Levine, 1997) . Post-translational modi®cation is thought to activate p53 and signal its nuclear accumulation following DNA damage. Nuclear localization is mediated, in part, by three well-de®ned nuclear localization signals (NLSs) clustered in p53s C-terminus (Shaulsky et al., 1990) . NLSI is the principal localization signal and is located between residues 315 ± 321. NLSII and NLSIII are located between residues 369 ± 375 and 379 ± 384, respectively. Notwithstanding the contribution of these NLSs to p53 localization, a lysine residue at position 305 and an arginine at position 306 are key determinants of p53 nuclear localization. Mutation of either of these residues abolished p53 nuclear import in transiently transfected cells (Liang et al., 1998; Liang and Clarke, 1999) .
In addition to nuclear import, the regulated nuclear export of p53 is also an important determinant of p53 activity. Wild-type p53 accumulates in the nucleus and is stabilized in cells exposed to leptomycin B (LMB), a speci®c inhibitor of nuclear export (Freedman and Stommel et al., 1999) . These ®ndings indicate that nuclear export is required for p53 degradation. Further, LMB treatment inhibited the ability of MDM2 to promote p53 degradation in transiently transfected cells Roth et al., 1998) . Given that MDM2 promotes p53 degradation via the ubiquitin proteolysis pathway, these results suggested that ubiquitinated p53 is degraded by proteasomes located in the cytoplasm. However, it has not been clari®ed in which cellular compartment p53 ubiquitination occurs, and whether blocking nuclear export would also inhibit MDM2-mediated p53 ubiquitination.
The purpose of the current study was to examine the role of nuclear localization in MDM2-dependent p53 ubiquitination. Towards this end, p53 localization and ubiquitinated p53 levels were monitored in cells treated with LMB to inhibit nuclear export. In addition, p53 levels and ubiquitination were monitored in cells expressing p53 and MDM2 proteins that localize to either the nucleus or the cytoplasm. Our results indicate that nuclear export is not required for p53 ubiquitination, and that p53 proteins that localize to either the nucleus or cytoplasm can be ubiquitinated and degraded by MDM2.
Results
Several studies have suggested that nuclear export is an important determinant of p53 stability. For example, wild-type p53 was stabilized in the nucleus of cells exposed to leptomycin B (LMB), a speci®c inhibitor of nuclear export Stommel et al., 1999) . Further, LMB treatment inhibited MDM2-dependent p53 degradation in cells transfected with p53 and MDM2 expression DNAs (Freedman and Roth et al., 1998) . These results suggested that p53 degradation requires the transport of p53 from the nucleus to the cytoplasm. However, it has not been clari®ed in which cellular compartment MDM2 promotes p53 ubiquitination, and whether blocking nuclear export would also block ubiquitination. To address this issue, U2OS cells were transfected with epitope-tagged p53 (HA-p53) and wild-type MDM2, and subsequently treated with LMB to block nuclear export. Ubiquitinated and non-ubiquitinated p53 levels were then assessed by immunoblot analysis with an anti-HA antibody (Figure 1a, b) . HA-p53 levels were reduced in cells cotransfected with HA-p53 and MDM2, indicative of MDM2-mediated degradation. In contrast, p53 degradation was partially inhibited when the transfected cells were treated with LMB for 3 or 6 h. This is consistent with previous studies which have indicated that nuclear export is required for MDM2 to degrade p53 (Freedman and Roth et al., 1998) . A ladder of high molecular weight p53 bands were observed when the transfected cells were treated with LMB for 3 or 6 h. We have previously con®rmed that these bands are HA-p53:ubiquitin conjugates by the fact that they shift in molecular weight and are recognized by anti-myc antibodies in transfections that included DNA encoding myc-tagged ubiquitin (Maki, 1999) . The eect of LMB was also examined in non-transfected U2OS cells. As expected, p53 steady-state levels were increased in the LMB-treated cells, due to stabilization of the protein (Figure 1d ). MDM2 levels were also increased following LMB treatment, suggesting that the stabilized p53 protein could activate MDM2 gene transcription. Importantly, a ladder of bands that were previously identi®ed as ubiquitin:p53 conjugates accumulated in the LMB treated cells (Figure 1c ) (Maki et al., 1996) . We recently demonstrated that p53 and MDM2, as well as the ubiquitinated forms of p53, are localized in the nucleus of LMB-treated U2OS cells (Geyer et al., 2000) . Taken together, these results indicate that nuclear export is not required for p53 ubiquitination, and suggest that MDM2-mediated ubiquitination of p53 can occur in the nucleus.
It is worth noting that in other studies we examined the eect of LMB on a second protein (beta-catenin) that is thought to be ubiquitinated and degraded by cytoplasmic proteasomes. In these studies, ubiquitin:-conjugates of beta-catenin accumulated in cells treated with the proteasome inhibitor MG132, but not in cells treated with LMB (not shown). These results suggest that LMB does not inhibit the proteasome. Based on these results, as well as those in Figure 1 and our previous study (Geyer et al., 2000) , we suggest that the accumulation of ubiquitinated p53 in LMB-treated cells results largely, if not entirely, from an inhibition of nuclear export and is not due to an inhibitory eect of LMB on proteasome activity.
We next wished to determine whether the ubiquitination of p53 is restricted to the nucleus, or whether it can also occur in the cytoplasm. Towards this end, p53 mutants were generated which localize to either the nucleus or the cytoplasm, and their susceptibility to ubiquitination by MDM2 was assessed. To generate cytoplasmic p53, the lysine at position 305 was converted to asparagine, resulting in the clone p53 (K305N). This mutation was previously shown to completely abolish p53 nuclear import in transiently transfected cells (Liang et al., 1998) . To generate p53 that localizes to the nucleus, the leucine residues at positions 348 and 350 were converted to alanine, resulting in the clone p53 (L348, 350A). These mutations disrupt the nuclear export signal (NES), and cause p53 to be retained in the nucleus (Stommel et al., 1999) . Wild-type p53 and each of the mutant p53 DNAs were transfected into U2OS cells alone, or cotransfected with MDM2, and their localization was assessed by immuno¯uorescence. As expected, wildtype p53 and p53 (L348, 350A) localized to the nucleus when expressed alone, while p53 (K305N) localized to the cytoplasm (Figure 2a ). When coexpressed with MDM2, wild-type p53 displayed both nuclear and cytoplasmic staining, while MDM2 remained nuclear ( Figure 2b ). This is consistent with studies suggesting that MDM2 can promote the export of p53 from the nucleus to the cytoplasm (Freedman and Roth et al., 1999; Geyer et al., 2000) . In contrast, p53 (L348, 350A) and MDM2 both localized to the nucleus when expressed together. Interestingly, p53 (K305N) was cytoplasmic when expressed alone, but localized largely to the nucleus when expressed with MDM2 ( Figure 2b ). This suggests that MDM2 can transport p53 (K305N) from the cytoplasm into the nucleus, perhaps via the nuclear localization signal (NLS) in MDM2.
Levels of ubiquitinated and non-ubiquitinated p53 were then assessed in the transfected cells by immunoblot analysis ( Figure 3 ). As shown in Figure 3a , MDM2 could eciently ubiquitinate wild-type p53 and each of the p53 mutants. Slightly higher levels of ubiquitination were observed for the p53 (L348, 350A) mutant than for wild-type p53 or p53 (K305N), probably because the p53 (L348, 350A) mutant was expressed at higher levels in this experiment. The fact that p53 (L348, 350A) localized in the nucleus and was eciently ubiquitinated by MDM2 indicates that p53 ubiquitination can occur in the nucleus. Steady state levels of wild-type p53 and each of the p53 mutants were decreased with MDM2 expression (middle panel Figure 3 ). The decreased steady-state levels of p53 are consistent with MDM2-mediated degradation. In these experiments, wild-type p53 and the p53 (K305N) mutant appeared to be degraded to a comparable extent when expressed with wild-type MDM2, and the p53 (L348, 350A) mutant was also degraded, though slightly less well.
Because p53 (K305N) localized to the nucleus when expressed with wild-type MDM2, we were unable to determine whether ubiquitination can occur in the cytoplasm, or whether it is restricted to the nucleus. Point mutations in the nuclear localization signal (NLS) of MDM2 have been reported to block MDM2s nuclear import (Tao and Levine, 1999) . Therefore, we generated an MDM2 mutant [designated MDM2 (NLS7)] in which the NLS sequence was mutated, and monitored its ability to ubiquitinate p53. Immunouorescence analysis demonstrated that wild-type MDM2 was nuclear in transfected U2OS cells, while MDM2 (NLS7) was cytoplasmic and nuclear (not shown). MDM2 (NLS7) localized to the nucleus and cytoplasm when expressed with wild-type p53, and was entirely nuclear when expressed with p53 (L348, 350A) ( Figure 4 ). In contrast, MDM2 (NLS7) and p53 (K305N) localized to the cytoplasm of cotransfected cells. The staining pattern for p53 (K305N) and MDM2 (NLS7) was scored in multiple experiments. In these analyses, p53 (K305N) displayed complete cytoplasmic staining (similar to that shown in Figure 4 ) in approximately 85% of cells in which it was expressed with MDM2 (NLS7), while the remaining 15% displayed strong cytoplasmic staining and only weak nuclear staining for p53 (K305N). Finally, we tested whether MDM2 (NLS7) could ubiquitinate wild-type p53 or either of the p53 localization mutants. As shown in Figure 5 , MDM2 (NLS7) was able to ubiquitinate wild-type p53, as well as p53 (L348, 350A) and p53 (K305N) to comparable levels. Further, steady-state levels of the wild-type and Figure 1 Leptomycin B stabilizes p53 without blocking ubiquitination. (a) U2OS cells were transfected with DNAs encoding HA-tagged p53 (2 mg) and MDM2 (8 mg) as indicated. Twentyfour hours later, the transfected cells were either untreated or exposed to leptomycin B for 3 or 6 h and protein extracts were prepared. Fifty mg of each extract was examined by immunoblot analysis with the anti-HA monoclonal antibody HA.11. The ®rst lane is non-transfected cells. The ladder of bands is ubiquitinated p53 (lower) MDM2 levels were monitored in the transfected cells by stripping the blot and reprobing with the MDM2 monoclonal antibody SMP-14. (b) A shorter exposure of the blot in (a) above was scanned by densitometry for quantitation of non-ubiquitinated HA-p53 levels in each lane. The level of HAp53 in the cells transfected with HAp53 only was considered 100% and all other values are relative to it. (c) U2OS cells (non-transfected) were untreated or treated with leptomycin B for 5 h. p53 was immunoprecipitated with the p53 monoclonal antibody Ab-2 (Oncogene Science), and the immunoprecipitates were examined by immunoblot analysis with the p53 monoclonal antibody Ab-6 (Oncogene Science). The ladder of bands were previously recognized as ubiquitin : p53 conjugates (Maki et al., 1996; Maki and Howley, 1997) . The asterisk marks the position of nonubiquitinated p53 as well as the antibody heavy chain used in the in the cytoplasm, we conclude that MDM2-dependent ubiquitination of p53 can occur in the cytoplasm.
Discussion
Wild-type p53 is a short-lived protein, with a reported half-life varying from 20 min to 4 h (Maltzman and Czyzyk, 1984; Maki and Howley, 1997; Hubbert et al., 1992) . Current models suggest that nuclear export is required for p53 degradation. However, the role of MDM2 in promoting p53 nuclear export has been a matter of debate. Tao and Levine (1999) reported that an MDM2 protein which localized exclusively to the cytoplasm was defective in promoting p53 degradation when expressed with p53 alone, or when coexpressed with p53 and an MDM2 mutant that localized exclusively to the nucleus. These ®ndings suggested that MDM2 shuttles between the nucleus and the cytoplasm, carrying p53 out of the nucleus so that it can be degraded by cytoplasmic proteasomes. In con¯ict with this model are ®ndings that p53 contains its own nuclear export sequence (NES), and that this NES is sucient to promote p53 nuclear export even in cells that lack MDM2 (Stommel et al., 1999) . Recent studies have attempted to clarify the role of MDM2 in p53 nuclear export (Geyer et al., 2000; Boyd et al., 2000) . In these studies it was found that MDM2 can promote p53 nuclear export in transiently transfected cells, and that this export requires the p53 NES. Interestingly, mutations in the MDM2 RING-®nger domain that inhibited p53 ubiquitination also inhibited p53 nuclear export. These results suggested that ubiquitination, or other activities associated with the MDM2 RING-®nger, is required to promote p53 nuclear export via the p53 NES. Why nuclear export would be required for p53 degradation is unknown. One possibility is that the ubiquitin system enzymes which cooperate with MDM2 to ubiquitinate p53 are found only in the cytoplasm and not in the nucleus. We do not favor this possibility for two reasons: First, previous studies demonstrated that ubiquitinated p53 levels were increased in cells treated with ionizing radiation (Maki and Howley, 1997) , and in these same cells, p53 and MDM2 accumulated in the nucleus. Second, ubiquitinated p53 levels increased in cells treated with the nuclear export inhibitor leptomycin B (Geyer et al., 2000; and Figure 1 ). These results indicate that nuclear export is not required for p53 ubiquitination, and that the factors which participate with MDM2 to promote p53 ubiquitination must be present in the nucleus. However, results from the current study also show that a p53 NLS7 mutant which localizes to the cytoplasm can be ubiquitinated by an MDM2 mutant that is similarly localized to the cytoplasm ( Figure 5 ). Taken together, these ®ndings indicate that the MDM2-mediated ubiquitination of p53 can occur in both the nucleus and the cytoplasm, and is not restricted to either cellular compartment.
It was previously reported that an MDM2 mutant that localized to the cytoplasm was de®cient in promoting wild-type p53 degradation (Tao and Levine, 1999) . However, it was not determined whether the cytoplasmic MDM2 mutant colocalized with p53 in the nucleus in these studies, or remained sequestered in the cytoplasm and separated from the wild-type p53 protein. In the current report, an MDM2 NLS7 mutant that localized to the cytoplasm could promote the ubiquitination and degradation of a p53 NLS7 mutant which also localized to the cytoplasm. Given that the MDM2 and p53 NLS7 mutants lack their nuclear import signals and therefore do not enter the nucleus, these results indicate that nuclear export per se of p53 and MDM2 is not required for p53 degradation. Our results also raise the possibility that p53 degradation is not restricted to the cytoplasm, but may also occur in the nucleus. For example, the p53 (L348, 350A) mutant was ubiquitinated and its levels decreased when expressed with wild-type MDM2 or the MDM2 NLS7 mutant, despite the fact that both proteins colocalized in the nucleus (Figures 2 and 4) . Further, the MDM2-mediated degradation of p53 was partially, though not entirely, inhibited in cells treated with LMB (Figure 1 ). Thus, while nuclear export may be required for the ecient degradation of p53 under most circumstances, these results suggest that p53 degradation may also occur, at least to some extent, in the nucleus. This would exclude the possibility that p53 can be degraded only by cytoplasmic proteasomes, but not by nuclear proteasomes.
An interesting ®nding from this study was that p53 and MDM2 colocalized almost entirely to the cytoplasm only when the nuclear localization of both proteins was inhibited. In contrast, MDM2 (NLS7) was completely nuclear when expressed with p53 (L348, 350A), and p53 (K305N) was largely nuclear when expressed with wild-type MDM2. These results suggest that p53 and MDM2 may facilitate the import of each other from the cytoplasm into the nucleus. This is consistent with a recent study in which p53 and its homologue p73b could relocalize a nuclear localization mutant of MDM2 from the cytoplasm to the nucleus (Dobblestein et al., 1999) .
The extent to which p53 ubiquitination may occur in either the nucleus or cytoplasm of normal cells is unknown. The amount of p53 found in the cytoplasm of normal, unstressed cells can vary during the cell cycle (David-Pfeuty et al., 1996; Fontoura et al., 1997) . Further, p53 can interact with ribosomal protein L5 and 5.8S ribosomal RNA (Fontoura et al., 1997; Abou Elela et al., 1997; Guerra and Issinger, 1998) , suggesting that p53 may play a role in protein translation by virtue of its association with active ribosomal complexes. Thus, while ubiquitination in the nucleus may be an eective means to inhibit the transactivation function of p53, ubiquitination in the cytoplasm may also serve to rapidly inhibit any putative cytoplasmic functions of p53.
Materials and methods

Plasmid DNAs
HA-tagged wild-type p53 expression plasmid was obtained from Christine Jost (Dana Farber Cancer Institute, USA). Wild-type MDM2 DNA was from Steve Grossmann (Dana Farber Cancer Institute, USA). p53 and MDM2 localization mutants were generated using the Quick-Change mutagenesis kit (Stratagene). The following oligonucleotides and their complementary oligonucleotides were used for the mutagenesis. For p53 (L348, 350A). 5'-GAGGCCGCGGAAGC-CAAGGATGCCCAGGCTGGG-3'). For p53 (K305N) 5'-CCCCCAGGGAGCACTAATCGAGCACTGCCCAAC-3'). For MDM2 (NLS7) 5'-CTGGTGAACGACAAACAAAG-CTTCACAAATCTGATAG-3').
Tissue culture and immunofluorescence U2OS cells were grown in Dulbeccos modi®ed Eagle media (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 ug/ml penicillin and streptomycin. Transfections were done using the calcium-phosphate method in 60 mm dishes when the cells were approximately 80% con¯uent. Either 2 or 5 mg of HA-tagged p53 DNA was transfected with either 5 or 8 mg of wild-type MDM2 DNA. The total DNA amount in each transfection was adjusted to 10 mg by the addition of salmon sperm DNA. Sixteen hours after the addition of the DNA precipitate, cells were washed twice with DMEM minus serum, and refed with DMEM plus 10% FBS. Where indicated, leptomycin B (generously provided by Minoura Yoshida, Tokyo University, Japan) was added to the culture media to a ®nal concentration of 60 ng/ml, and extracts were prepared 3 ± 8 h later. For immuno¯uorescence staining, cells were plated onto glass cover slips prior to transfection. p53 staining was carried out using the anti-HA polyclonal antibody HA.11 (Babco). MDM2 staining was carried out using the anti-MDM2 monoclonal antibody SMP-14 (Santa Cruz).
Immunoblots
Cells were rinsed with phosphate buered saline (PBS) and scraped into 800 ml radioimmunoprecipitation (RIPA) buer (2 mM Tris [Ph 7.5], 5 mM EDTA, 150 mM NaCl, 1.0% Nonidet P-40, 1.0% deoxycholate, 0.025% SDS, 1 mM phenylmethylsulfonyl¯uoride [PMSF] ). Cells were then sonicated for 10 pulses at setting 5, 50% output, with a Branson 450 soni®er, and spun at 15 000 g for 15 min. to remove cellular debris. Protein extracts were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE), and transferred to an Immobilon-P membrane. The membrane was probed with either an anti-HA monoclonal antibody (HA.11 from Babco) to detect the transfected p53 protein, or with the MDM2 antibody SMP-14 (Santa Cruz).
